Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ESPR
SELLEsperion Therapeutics, Inc. · Healthcare · United States · $817M · Avg Vol: $46M/d
COMPANY DESCRIPTION
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated LDL-cholesterol (LDL-C) and other cardiovascular risk factors. The company's approved products, NEXLETOL® and NEXLIZET®, offer new treatment options for individuals unable to reach cholesterol goals with statins or those who are statin intolerant. Esperion holds a niche position in the cardiovascular drug market, addressing unmet needs in dyslipidemia management.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.5M | 116.3M | 332.3M | 403.1M | 74.8% | 418.2M | 337.6M | 439.0M | 4.3% |
| EPS | -1.02 | -0.93 | -0.28 | -0.11 | — | — | — | — | — |
| Shares | 257.7M | 257.7M | 195.9M | 245.2M | -4.8% | 257.7M | — | — | — |
| Debt | 260.9M | 266.2M | 297.6M | 252.2M | -1.1% | 543.8M | — | — | — |
| Equity | -323.8M | -455.0M | -388.7M | -302.0M | — | — | — | — | — |
| Op CF | -174.8M | -135.5M | -23.7M | -13.1M | — | -18.2M | — | — | — |
| Inv CF | 8.1M | 42.5M | -0.3M | 0 | — | — | — | — | — |
| Fin CF | 32.6M | 50.5M | 86.5M | 36.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ESPR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ESPR | Esperion Therapeutics, Inc.(you) | $817M | 33 | SELL |
| GLAS | Glass House Brands Inc. | $899M | 35 | HOLD |
| BIOA | BioAge Labs, Inc. | $968M | 31 | SELL |
| VREO.CN | Vireo Growth Inc. | $500M | 36 | HOLD |
| HROW | Harrow, Inc. | $1.5B | 35 | SELL |
| AKBA | Akebia Therapeutics, Inc. | $327M | 33 | SELL |
| EOLS | Evolus, Inc. | $394M | 39 | HOLD |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.0B | 28 | SELL |
| ORGO | Organogenesis Holdings Inc. | $308M | 39 | HOLD |
| TKNO | Alpha Teknova, Inc. | $266M | 36 | HOLD |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%